188 related articles for article (PubMed ID: 26755047)
1. Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer.
Bussmann L; Busch CJ; Lörincz BB; Rieckmann T; Block A; Knecht R
Eur Arch Otorhinolaryngol; 2016 Dec; 273(12):4073-4080. PubMed ID: 26755047
[TBL] [Abstract][Full Text] [Related]
2. Is there a role for chemosensitivity tests in head and neck cancer?
Dollner R; Granzow C; Werner JA; Dietz A
Onkologie; 2004 Jun; 27(3):310-5. PubMed ID: 15249723
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
Hasegawa Y; Goto M; Hanai N; Ijichi K; Adachi M; Terada A; Hyodo I; Ogawa T; Furukawa T
Oral Oncol; 2007 Sep; 43(8):749-56. PubMed ID: 17112769
[TBL] [Abstract][Full Text] [Related]
4. [Molecular mechanisms of chemoresistance in head and neck squamous cell carcinoma].
Zhao YX; Sun ZF
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jun; 31(11):888-891. PubMed ID: 29775010
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo responsiveness of head and neck squamous cell carcinoma to vinorelbine.
Dollner R; Granzow C; Tschop K; Dietz A
Anticancer Res; 2006; 26(3B):2361-5. PubMed ID: 16821617
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab and the Head and Neck Squamous Cell Cancer.
Concu R; Cordeiro MNDS
Curr Top Med Chem; 2018; 18(3):192-198. PubMed ID: 29332581
[TBL] [Abstract][Full Text] [Related]
7. [Chemosensitivity testing of anticancer agents in head and neck tumors. I: Comparison between head and neck squamous cell cancers and thyroid cancers].
Nakashima T; Tomita K; Kuratomi Y; Maehara Y; Kohnoe S
Gan To Kagaku Ryoho; 1990 Jan; 17(1):79-84. PubMed ID: 2297240
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations.
Dollner R; Granzow C; Neudert M; Dietz A
Anticancer Res; 2006; 26(2B):1651-5. PubMed ID: 16619587
[TBL] [Abstract][Full Text] [Related]
9. Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs.
Blasco MA; Svider PF; Raza SN; Jacobs JR; Folbe AJ; Saraf P; Eloy JA; Baredes S; Fribley AM
Laryngoscope; 2017 Nov; 127(11):2565-2569. PubMed ID: 28581126
[TBL] [Abstract][Full Text] [Related]
10. The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma.
Dollner R; Granzow C; Helmke BM; Ruess A; Schad A; Dietz A
Anticancer Res; 2004; 24(1):325-31. PubMed ID: 15015616
[TBL] [Abstract][Full Text] [Related]
11. [Preclinical models to establish innovative therapy strategies : Ex‑vivo assessment of head and neck tumor chemo- and immune responses].
Wichmann G; Dietz A
HNO; 2016 Jul; 64(7):460-9. PubMed ID: 27259639
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy for squamous-cell carcinoma of the head and neck.
Papaspyrou G; Werner JA; Dietz A
Expert Opin Pharmacother; 2011 Feb; 12(3):397-409. PubMed ID: 21254947
[TBL] [Abstract][Full Text] [Related]
13. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
14. Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma.
Hasegawa Y; Goto M; Hanai N; Ijichi K; Terada A; Hyodo I; Ogawa T; Fukushima M
Oncology; 2007; 73(1-2):104-11. PubMed ID: 18337622
[TBL] [Abstract][Full Text] [Related]
15. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo responsiveness of head and neck squamous cell carcinoma to glufosfamide, a novel alkylating agent.
Dollner R; Dietz A; Kopun M; Helbig M; Wallner F; Granzow C
Anticancer Res; 2004; 24(5A):2947-51. PubMed ID: 15517901
[TBL] [Abstract][Full Text] [Related]
17. The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas.
Martinez-Useros J; Garcia-Foncillas J
Oral Oncol; 2015 May; 51(5):423-30. PubMed ID: 25753560
[TBL] [Abstract][Full Text] [Related]
18. Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Correlations with clinical response to cisplatin.
Robbins KT; Connors KM; Storniolo AM; Hanchett C; Hoffman RM
Arch Otolaryngol Head Neck Surg; 1994 Mar; 120(3):288-92. PubMed ID: 8123238
[TBL] [Abstract][Full Text] [Related]
19. Management and palliative chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck.
Machiels JP; Schmitz S
Expert Rev Anticancer Ther; 2011 Mar; 11(3):359-71. PubMed ID: 21534878
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo culture of head and neck cancer explants in cell sheet for testing chemotherapeutic sensitivity.
Lee J; You JH; Shin D; Roh JL
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2497-2507. PubMed ID: 32620987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
